Tags

Type your tag names separated by a space and hit enter

Prognostic Significance of c-MYC Amplification in Esophageal Squamous Cell Carcinoma.
Ann Thorac Surg. 2019 02; 107(2):436-443.AT

Abstract

BACKGROUND

We investigated the frequency of c-MYC amplification in esophageal squamous cell carcinoma (ESCC), including both stage I to II and III to IVa disease, and evaluated the correlation of c-MYC amplification with clinicopathologic variables and outcome.

METHODS

In 259 ESCCs resected at Zhongshan Hospital, Fudan University, from January 2007 to November 2010, c-MYC amplification was analyzed by using tissue microarray, with fluorescence in situ hybridization assay.

RESULTS

c-MYC gene amplification was found in 43.2% (112 of 259) of patients with ESCC. Significant differences were found between c-MYC amplification and patient age (p = 0.009) and lymph node metastasis (p = 0.046). The median follow-up period was 33 months (range: 4 to 102 months). A survival difference was found between patients with different c-MYC status. Among 112 patients with c-MYC amplification, a significantly poorer prognosis was observed, with a median disease-free survival (DFS) and overall survival (OS) of 24.0 and 31.0 months compared with 48.0 and 48.0 months, respectively, for patients without c-MYC amplification (p = 0.011 and 0.018). On univariate and multivariate analysis, site, clinical stage, lymph node metastasis, adjuvant therapy, and c-MYC amplification were associated with DFS and OS. When patients were divided into stage I to II and stage III to IV subgroups, c-MYC amplification tended to associate with poorer survival but without statistical difference (p > 0.05).

CONCLUSIONS

c-MYC amplification was associated with age and lymph node metastasis and was an independent poor-prognostic factor for DFS and OS in the full cohort of patients with ESCC.

Authors+Show Affiliations

Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.Department of Pathology, Qingpu Branch of Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.Department of Pathology, School of Basic Medical Sciences and Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.Department of Pathology, Qingpu Branch of Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China; Department of Pathology, Qingpu Branch of Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China; Department of Pathology, School of Basic Medical Sciences and Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China. Electronic address: houyingyong@aliyun.com.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

30273571

Citation

Huang, Jie, et al. "Prognostic Significance of c-MYC Amplification in Esophageal Squamous Cell Carcinoma." The Annals of Thoracic Surgery, vol. 107, no. 2, 2019, pp. 436-443.
Huang J, Jiang D, Zhu T, et al. Prognostic Significance of c-MYC Amplification in Esophageal Squamous Cell Carcinoma. Ann Thorac Surg. 2019;107(2):436-443.
Huang, J., Jiang, D., Zhu, T., Wang, Y., Wang, H., Wang, Q., Tan, L., Zhu, H., Yao, J., & Hou, Y. (2019). Prognostic Significance of c-MYC Amplification in Esophageal Squamous Cell Carcinoma. The Annals of Thoracic Surgery, 107(2), 436-443. https://doi.org/10.1016/j.athoracsur.2018.07.077
Huang J, et al. Prognostic Significance of c-MYC Amplification in Esophageal Squamous Cell Carcinoma. Ann Thorac Surg. 2019;107(2):436-443. PubMed PMID: 30273571.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Prognostic Significance of c-MYC Amplification in Esophageal Squamous Cell Carcinoma. AU - Huang,Jie, AU - Jiang,Dongxian, AU - Zhu,Ting, AU - Wang,Yanqiu, AU - Wang,Hao, AU - Wang,Qun, AU - Tan,Lijie, AU - Zhu,Hongguang, AU - Yao,Junxia, AU - Hou,Yingyong, Y1 - 2018/09/28/ PY - 2017/09/20/received PY - 2018/07/23/revised PY - 2018/07/24/accepted PY - 2018/10/3/pubmed PY - 2019/11/8/medline PY - 2018/10/2/entrez SP - 436 EP - 443 JF - The Annals of thoracic surgery JO - Ann. Thorac. Surg. VL - 107 IS - 2 N2 - BACKGROUND: We investigated the frequency of c-MYC amplification in esophageal squamous cell carcinoma (ESCC), including both stage I to II and III to IVa disease, and evaluated the correlation of c-MYC amplification with clinicopathologic variables and outcome. METHODS: In 259 ESCCs resected at Zhongshan Hospital, Fudan University, from January 2007 to November 2010, c-MYC amplification was analyzed by using tissue microarray, with fluorescence in situ hybridization assay. RESULTS: c-MYC gene amplification was found in 43.2% (112 of 259) of patients with ESCC. Significant differences were found between c-MYC amplification and patient age (p = 0.009) and lymph node metastasis (p = 0.046). The median follow-up period was 33 months (range: 4 to 102 months). A survival difference was found between patients with different c-MYC status. Among 112 patients with c-MYC amplification, a significantly poorer prognosis was observed, with a median disease-free survival (DFS) and overall survival (OS) of 24.0 and 31.0 months compared with 48.0 and 48.0 months, respectively, for patients without c-MYC amplification (p = 0.011 and 0.018). On univariate and multivariate analysis, site, clinical stage, lymph node metastasis, adjuvant therapy, and c-MYC amplification were associated with DFS and OS. When patients were divided into stage I to II and stage III to IV subgroups, c-MYC amplification tended to associate with poorer survival but without statistical difference (p > 0.05). CONCLUSIONS: c-MYC amplification was associated with age and lymph node metastasis and was an independent poor-prognostic factor for DFS and OS in the full cohort of patients with ESCC. SN - 1552-6259 UR - https://www.unboundmedicine.com/medline/citation/30273571/Prognostic_Significance_of_c_MYC_Amplification_in_Esophageal_Squamous_Cell_Carcinoma_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0003-4975(18)31331-6 DB - PRIME DP - Unbound Medicine ER -